Zdrowie i gospodarka · 16/01/2024
Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings
The National Institute for Occupational Safety and Health (NIOSH) requests public comment on draft reevaluations to change the status of liraglutide and pertuzumab on the NIOSH List of Antineoplastics and Other Hazardous Drugs in Healthcare Settings, recommending their removal.